IPCI has a very large and attractive Product Pipeline with 8 Drugs awaiting FDA approval which could they could approved anytime now . Their Key Drug is Rexista a potential Best in Class Abuse Deterrent Pain Drug with HUGE Market Potential . NDA Filing for the Drug is planned within Weeks (June or July) .We could see $5++ easily with NDA filing and Runup to FDA decision (4Q16 or early 1Q2017) and much higher if there is any approval of the Drugs under review by FDA . This ultra Low float Stock is a lifetime opportunity here close at ATL . GL Intellipharmaceutics (Nasdaq: IPCI) Market Cap: $44 Million Cash: $6 Million Price: $1.59 Shares Out: 28 Million Slide Presentation http://files.shareholder.com/downlo...stor_Conference_March_2016_upload_version.pdf Dialing Back Euphoria: The Intellipharmaceutics Prescription for Opioid Abuse https://www.streetwisereports.com/p...intellipharmaceutics-solution-to-opioid-abuse James bond’-like tech is the end to overdoses, says formulation firm http://www.in-pharmatechnologist.co...is-the-end-to-overdoses-says-formulation-firm Intellipharmaceutics(IPCI-NASDAQ, Speculative Buy, US$12 target) Intellipharmaceutics International Inc.: Investors should focus on Rexista Oxycodone XR (pain) targeting a US$2.3 billion market. On May 21, FDA gave guidance to IPCI that the Rexista NDA could be filed without a Phase 3 trial if they could demonstrate bioequivalence to Oxycontin. By IPCI only having to do a bioequivalence trial for Rexista Oxycodone XR, compared to Purdue’s Oxycontin, the company will now run a smaller trial of only 24-40 patients. IPCI should be able to file for FDA approval in H1 2016. There are several catalysts for IPCI expected: (i) clinical results for the Rexista oxycodone pharmacokinetic studies (fed and fasting) likely in November 2015 (ii) an NDA filing for Rexista Oxycodone in H1 2015 (iii) 7 ANDA approvals could come at any point as the generic arm of the FDA clears its backlog and (iv) management has been actively working on licensing its products (generics and brand) such a transaction could be forged in H1 2016. On May 26, FDA granted Rexista Oxycodone XR fast track designation. With a “fast track designation” for Rexista Oxycodone XR, it is possible the NDA could be reviewed in 6 months or less and the drug could be launched at the end of 2016/H1 2017 (we have modeled in a mid 2017 to H2 2017 launch which is now very conservative). Additionally, multiple ANDA (generic) approvals are expected including: Glucophage XR ANDA filed on August 2010, Effexor XR ANDA filed January 2010, Protonix ANDA filed June 2010, Seroquel XR ANDA filed February 2011, Lamictal XR ANDA filed September 2011, Keppra XR ANDA filed June 2012 and Pristiq ANDA filed September 2012. The timing of ANDA approvals cannot be predicted, but they are long overdue based on historical precedents. It now appears the FDA is attempting to clear its backlog of ANDAs, as the Office of Generic Drugs (OGD) broke its old post-GDUFA approvals record of 57 by one, issuing 58 full ANDA approvals in August 2015.The company has the option to license all of its products which are not partnered – this would provide non-dilutive financing.
Founder and Ceo is the largest shareholder holding 5,8 Million shares (20%) . The small Share Offering closed yesterday so a run back over $2 could start anytime now .GL Dr. Isa Odidi of Intellipharmaceutics (Nasdaq:IPCI) (TSX:I) is easily one of the sector's genius drug delivery innovators. While he was at Biovail, Odidi was performing drug alchemy with formulations that mimicked several hard-to-manufacture generic versions of expensive drugs- among them, Pfizer’s (NYSEFE) Procardia XL, Bayer’s (BAYRY.PK) Adalat CC, and Novartis’ (NYSE:NVS) Voltaren XR. While serving as the company’s Vice President of Research of Drug Development and New Technologies he helped grow Biovail through its adolescence. As difficult as the scientific process was, the business plan was simple. Odidi and his team worked out the chemical composition to develop the drugs and pushed their versions through the regulatory process at the U.S. Food and Drug Administration. Once approved, the company licensed the drugs to different companies and collected royalties. While Odidi perfected his science and learned to navigate the FDA process, Biovail grew into a 10+billion market cap company
once the stock retake the MA(50) at 1.80 then quick jump back over $2 coming . IPCI is still one of the most undervalued Biotechs out there
IPCI had an FDA approval on Friday so it should uptick for the next few days, GLTA. February 24, 2017 Intellipharmaceutics Announces FDA Approval for 500 mg and 750 mg Generic Glucophage® XR TORONTO, Feb. 24, 2017 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs announced that the Company today received final approval from the U.S. Food and Drug Administration ("FDA") for the Company's abbreviated new drug application ("ANDA") for metformin hydrochloride extended release tablets in the 500 mg and 750 mg strengths. The Company's newly approved product is a generic equivalent for the corresponding strengths of the branded product Glucophage® XR sold in the United States by Bristol-Myers Squibb. Dr. Isa Odidi, the CEO and a co-founder of Intellipharmaceutics, stated, "FDA approval of our application for a generic version of Glucophage® XR provides further indication that the FDA is making progress to clear its backlog of ANDA drug candidates under review, and further validation of our core drug development and regulatory capability. We are encouraged that some of the Company's other 8 ANDA candidates may be accorded further attention soon. We are actively evaluating options to realize commercial returns from this new approval." Glucophage® XR, and the drug active metformin, are indicated for use in the management of type 2 diabetes treatment. According to Symphony Health Solutions, sales in the United States for the 12 months ended January 2017 of the 500 mg and 750 mg strengths of Glucophage® XR and all generic equivalents, were approximately $591 million (TRx MBS Dollars, which represents projected new and refilled prescriptions representing a standardized dollar metric based on manufacturer's published catalog or list prices to wholesalers, and does not represent actual transaction prices and does not include prompt pay or other discounts, rebates or reductions in price). The Company is aware that other generic versions of this product are currently available in the market. There can be no assurance that the Company's metformin extended-release tablets for the 500 mg and 750 mg strengths will be successfully commercialized.
This is good news as well, put this on your buy/watch list. Intellipharmaceutics International Inc. (IPCI) Receives Buy Rating from Aegis Feb 26th, 2017 Aegis reissued their buy rating on shares of Intellipharmaceutics International Inc. (NASDAQ:IPCI) (TSE:I) in a research report report published on Sunday morning. They currently have a $8.00 price target on the stock. Several other equities analysts have also recently issued reports on the company. Maxim Group set a $6.00 price target on Intellipharmaceutics International and gave the company a buy rating in a report on Friday, November 25th. Zacks Investment Research upgraded Intellipharmaceutics International from a sell rating to a hold rating in a report on Tuesday, December 27th. Intellipharmaceutics International opened at 2.55 on Friday. Intellipharmaceutics International has a 1-year low of $1.41 and a 1-year high of $3.35. The firm’s 50-day moving average price is $2.64 and its 200 day moving average price is $2.51. The stock’s market cap is $76.45 million. This news story was originally published by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this news story on another website, it was illegally copied and reposted in violation of U.S. and international copyright and trademark legislation. The legal version of this news story can be accessed at A hedge fund recently raised its stake in Intellipharmaceutics International stock. Atria Investments LLC boosted its stake in shares of Intellipharmaceutics International Inc. (NASDAQ:IPCI) (TSE:I) by 12.1% during the third quarter, according to its most recent filing with the SEC. The firm owned 75,895 shares of the company’s stock after buying an additional 8,168 shares during the period. Atria Investments LLC owned 0.26% of Intellipharmaceutics International worth $159,000 as of its most recent SEC filing. 1.49% of the stock is owned by hedge funds and other institutional investors.
Heads up: This is about to fly. They have so much going for them, I highly recommend, but don't buy because I suggested it, do some DD on this low float baby and you'll see. When this thread was started in June 2016 it was at $1.59 I predict it will hit $5 to $8 by June of this year without a buy out or partnership. GLTA "Zacks Investment Research Upgraded Intellipharmaceutics International Inc. (IPCI) to “Hold” "Intellipharmaceutics International (NASDAQ:IPCI) (TSE:I) had its buy rating reaffirmed by analysts at Aegis. The firm currently has a $8.00 target price on the stock." "Sell-side analysts are offering a consensus “Buy” rating on shares of IntelliPharmaCeutics International Inc. (NASDAQ:IPCI). Using the following ratings scale: 1.0 Strong Buy, 2.0 Buy, 3.0 Hold, 4.0 Sell and 5.0 Strong Sell, analysts have an average recommendation of 1.70. Based on a recent trade, the shares are hovering around $2.63 which, according to analysts, yield significant upside potential to the $6.67 consensus target price."
Great news is imminent Average Price Target Of 10.28 Issued For Intellipharmaceutics International Inc. (IPCI)
I wonder if we are seeing a cup and handle forming... the Technicals look like an excellent setup for a big move in the coming weeks
Market Cap $12 M / Cash balance $14 M / 6 Drugs awaiting FDA approval / NDA Resubmission for a BIG Pain Drug this Quarter FDA approval likely in 1H 2019 (more infos below) = HUGE upside potential Presentation October 2018 http://secfilings.nasdaq.com/filingFrameset.asp?FilingID=12999325&RcvdDate=10/5/2018& Mega Pipeline https://www.intellipharmaceutics.com/product-pipeline
